miRPOC - biomarkers for early detection of ovarian cancer
Project
|Last update
This study will provide validation of a panel of microRNAs for ovarian cancer early detection and direction of women with suspicion of cancer to specialist care.
Ovarian cancer is generally diagnosed at late stage, after the disease has spread, and the disease has poor survival. There are no effective early detection strategies, and early disease symptoms are non-specific (e.g., bloating, feeling of fullness). Biomarkers evaluated to date do not outperform the “best available” marker CA125; however, a preliminary study provided evidence that a serum microRNA profile may provide better differentiation between ovarian cancer cases and non-cases than CA125.
This study will provide validation of a microRNA panel for ovarian early detection in serum samples from prospective cohorts and clinical data and biospecimens. The overarching objective is to validate a serologic microRNA panel that, together with CA125, would have sufficient diagnostic discrimination for early-stage disease to be used as a tool that, complementary to imaging, would allow early diagnosis and direction of patients with suspected malignancy to personalized gyn-oncological care.
About the project
Principal Investigator: Renée Turzanski Fortner, PhD, Senior researcher, Cancer Registry of Norway
Researchers: Hilde Langseth, PhD, Senior researcher, Trine Rounge, PhD, Marcin Wojewodzic, PhD
Research support: Marianne Lauritzen, MSc, Katarina Baumgarten Skogstrøm, MSc
Collaborating centers:
- Rudolf Kaaks, PhD, German Cancer Research Center
- Konrad Stawiski, MD, PhD, Medical University of Lodz
- Kevin Elias, MD, Brigham and Women's Hospital/Harvard Medical School
- Marit Solbjør, PhD, Norwegian University of science and technology
REC: Ref. no. 551921
Duration: 2023 - ongoing
Funding: ERA PerMed 2022